Thomas P. Loughran Jr.
| Thomas P. Loughran, Jr., MD | |
|---|---|
 Thomas P. Loughran, Jr., MD | |
| Nationality | American |
| Fields | |
| Institutions | |
| Alma mater | Hahnemann Medical School |
Thomas P. Loughran, Jr., MD is an American physician scientist who specializes in cancer research and treatment. He became director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine at the University of Virginia on August 15, 2013.[1] Between 2003 and 2013, Loughran served as the founding director of the Penn State Hershey Cancer Institute and professor of medicine at the Penn State College of Medicine. His previous appointments included program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center and chief of hematology at the Syracuse Veteran’s Affairs Medical Center in Syracuse, N.Y.[2] Loughran completed his fellowship in medical oncology in 1985 at the Fred Hutchinson Cancer Research Center in Seattle, Washington under direction of Nobel Laureate E. Donnall Thomas. He remained on faculty there for seven years. Loughran earned his medical degree from Hahnemann Medical School in Philadelphia in 1979.[1]
LGL leukemia research
Loughran is internationally recognized for cancer research and treatment. His primary research interest is large granular lymphocyte leukemia (LGL), a hematologic malignancy he discovered in the mid-1980s.[3] He has received continuous federal grant support for the past 26 years and currently is the principal investigator on two RO1 grants and a PO1 grant from the National Cancer Institute, as well as a translational research grant from the Leukemia & Lymphoma Society. Loughran has published numerous articles in high impact peer-reviewed journals including ‘’The New England Journal of Medicine’’,[4] ‘’Annals of Internal Medicine’’,[5]’’The Lancet’’,[6] ‘’Journal of Clinical Investigation’’,[7] ’’Journal of Clinical Oncology’’,[8] and Blood[9] Loughran holds American Board certifications in internal medicine and medical oncology. In his clinical practice, he treats patients with bone marrow disorders and leukemia.[10]
References
- 1 2 "Thomas P. Loughran Jr., MD, appointed director of UVA Cancer Center". University of Virginia Health System Official Website. Retrieved 2013-11-21.
- ↑ "Observe, lead, discover". Ursinus Magazine Fall 2013. Retrieved 2013-11-21.
- ↑ "Hershey doctor's pioneering work with rare leukemia offers hope to patients worldwide". The Patriot-News. Retrieved 2013-11-25.
- ↑ "Somatic STAT3 mutations in large granular lymphocytic leukemia.". New England Journal of Medicine. Retrieved 2013-11-21.
- ↑ "Polyarthritis and neutropenia associated with circulating large granular lymphocytes.". Annals of Internal Medicine. Retrieved 2013-11-26.
- ↑ "Serum reactivity to human T-cell leukaemia/lymphoma virus type I proteins in patients with large granular lymphocytic leukaemia.". Lancet. Retrieved 2013-11-26.
- ↑ "NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.". Journal of Clinical Investigation. Retrieved 2013-11-26.
- ↑ "Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.". Journal of Clinical Oncology. Retrieved 2013-11-26.
- ↑ "STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.". Blood. Retrieved 2013-11-21.
- ↑ "Thomas Loughran, MD Cancer Center". University of Virginia Health System Official Website. Retrieved 2013-11-25.